Mergers & Acquisitions Mergers & Acquisitions

Illumina’s challenge to EU review of Grail deal fast-tracked by judges

By Lewis Crofts
  • 03 Jun 2021 13:38
  • 03 Jun 2021 13:51
Illumina’s appeal against a European Commission decision to take jurisdiction over the company’s acquisition of cancer-detection company Grail will be fast-tracked through the bloc’s courts after judges decided to review the case under an “expedited procedure.”
The US gene-sequencing company is challenging the commission’s acceptance of a request from France

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts

Editor-In-Chief


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News